Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: A retrospective analysis of 116 serotonin producing neuroendocrine tumour patients
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0112278
document
Purpose: This study evaluates the prevalence of cardiac metastases in patients with serotonin producing neuroendocrine tumours (NET), examined with F-18-FDOPA PET/CT, and the relationship of these metastases to the presence of carcinoid heart disease (CHD) based on echocardiography. Background: CHD occurs in patients with serotonin producing NET. The diagnostic method of choice remains echocardiography. The precise prevalence of cardiac metastases is unknown given the limitations of standard technologies. Nuclear medicine modalities have the potential to visualize metastases of NET. Methods: All patients who underwent F-18-FDOPA PET/CT because of...
Walter Noordzij, Andre P. van Beek, Rene A. Tio, Anouk N. van der Horst-Schrivers, Elisabeth G. de Vries, Bram van Ginkel, Annemiek M. Walenkamp, Andor W. Glaudemans, Riemer H. Slart, Rudi A. Dierckx
Comment on Aksoy et al. FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-014-2777-8
Elena Lazzeri, Ora Israel, Paola A. Erba, Riddhika Chakravartty, Joss Martin Comin, Francois Jamar, Francois Rouzet, Andor W. J. M. Glaudemans, Alberto Signore
1627PPET-IMAGING WITH 89ZR-LABELED ANTI-MESOTHELIN (MSLN) ANTIBODY IN PATIENTS WITH PANCREATIC CANCER (PC) OR OVARIAN CANCER (OC)
Published in: Annals of Oncology
Access to document
10.1093/annonc/mdu358.58
Aim: The tumor antigen MSLN is frequently overexpressed in PC and OC. A 89Zr-PET study (NCT01832116) with MMOT0530A, an anti-MSLN antibody, was initiated in conjunction with a phase 1 study of the antibody-drug conjugate DMOT4039A (containing MMOT0530A linked to the anti-mitotic agent MMAE, NCT01469793). This imaging study aims to investigate antibody tumor uptake, whole body distribution and organ pharmacokinetics and to explore the relation between uptake and MSLN expression and response to DMOT40392A treatment in patients with unresectable PC or platinum-resistant OC. Methods: Before receiving DMOT4039A, patients were...
L E Lamberts, C W Menke-van der Houven van Oordt, F Bensch, J Voortman, O S Hoekstra, D Maslyar, S P Williams, B M Fine, A H Bongaerts, J A Gietema, C P Schroder, E J Ter Weele, M N Lub-De Hooge, H M Verheul, S Sanabria, A W J M Glaudemans, Elisabeth G. E. Vries, de
In vivo and in vitro evidence that Tc-99m-HYNIC-interleukin-2 is able to detect T lymphocytes in vulnerable atherosclerotic plaques of the carotid artery
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-014-2764-0
Purpose Recent advances in basic science have established that inflammation plays a pivotal role in the pathogenesis of atherosclerosis. Inflammatory cells are thought to be responsible for the transformation of a stable plaque into a vulnerable one. Lymphocytes constitute at least 20 % of infiltrating cells in these vulnerable plaques. Therefore, the interleukin-2 (IL-2) receptor, being overexpressed on activated T lymphocytes, may represent an attractive biomarker for plaque vulnerability. The aim of this study was to evaluate the specificity of radiolabelled IL-2 [Tc-99m-hydrazinonicotinamide (HYNIC)-IL-2] for imaging the lymphocytic...
Andor W. J. M. Glaudemans, Elena Bonanno, Filippo Galli, Clark J. Zeebregts, Erik de Vries, Michel Koole, Gert Luurtsema, Hendrikus H. Boersma, Maurizio Taurino, Riemer H. J. A. Slart, Alberto Signore